About Profluent Bio
Profluent Bio is a company based in Berkeley (United States) founded in 2022 by Alexander Meeske and Ali Madani.. Profluent Bio has raised $150 million across 3 funding rounds from investors including Spark Capital, Insight Partners and Air Street Capital. Profluent Bio offers products and services including OpenCRISPR and ProGen3. Profluent Bio operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others.
- Headquarter Berkeley, United States
- Founders Alexander Meeske, Ali Madani
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Profluent Bio Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$150 M (USD)
in 3 rounds
-
Latest Funding Round
$106 M (USD), Series B
Nov 19, 2025
-
Investors
Spark Capital
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Profluent Bio
Profluent Bio offers a comprehensive portfolio of products and services, including OpenCRISPR and ProGen3. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI-designed editor for gene modification in biological applications
System for authoring proteins in medicine and agriculture
Unlock access to complete
Funding Insights of Profluent Bio
Profluent Bio has successfully raised a total of $150M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $106 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $106.0M
-
First Round
First Round
(26 Jan 2023)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Series B - Profluent Bio | Valuation | Altimeter Capital , Bezos Expeditions | |
| Mar, 2024 | Amount | Series A - Profluent Bio | Valuation | Spark Capital | |
| Jan, 2023 | Amount | Seed - Profluent Bio | Valuation | Insight Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Profluent Bio
Profluent Bio has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Spark Capital, Insight Partners and Air Street Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Spark Capital is engaged in venture capital investments.
|
Founded Year | Domain | Location | |
|
Investment firm scaling software and technology companies from early to late stages.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in AI & life science sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Profluent Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Profluent Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Profluent Bio Comparisons
Competitors of Profluent Bio
Profluent Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Chemoproteomics solutions are provided for protein design and development.
|
|
| domain | founded_year | HQ Location |
Provider of an AI models for protein design
|
|
| domain | founded_year | HQ Location |
Developer of proteins using protein engineering technology
|
|
| domain | founded_year | HQ Location |
Bioinformatics platform is developed for drug discovery and chemoproteomics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Profluent Bio
Frequently Asked Questions about Profluent Bio
When was Profluent Bio founded?
Profluent Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Where is Profluent Bio located?
Profluent Bio is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Who is the current CEO of Profluent Bio?
Ali Madani is the current CEO of Profluent Bio. They have also founded this company.
Is Profluent Bio a funded company?
Profluent Bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a Seed of $9M, raised on Jan 26, 2023.
What does Profluent Bio do?
Profluent Bio was founded in 2022 in Berkeley, United States. An artificial intelligence platform for protein design is offered within the biotechnology sector. Deep generative models are employed to create novel proteins with functional properties suitable for drug discovery applications. Operations center on advancing protein engineering techniques through computational methods, supporting research and development in therapeutics.
Who are the top competitors of Profluent Bio?
Profluent Bio's top competitors include Nimbus Therapeutics, Cradle and Eikon.
What products or services does Profluent Bio offer?
Profluent Bio offers OpenCRISPR and ProGen3.
Who are Profluent Bio's investors?
Profluent Bio has 8 investors. Key investors include Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Phoenix Venture Partners.